About Syntaxin
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.
Series B financing of $32m was finalised in October 2007. The fundraising round was co-led by new investors SR One, the venture capital arm of GSK, one of the world's leading research-based pharmaceutical and healthcare companies, and LSP (Life Science Partners) with additional funds from Syntaxin's existing shareholders, Abingworth. New investors Johnson & Johnson Development Corporation (JJDC) and Quest for Growth also participated in the financing.
